FINWIRES · TerminalLIVE
FINWIRES

Fraser and Neave Books Lower Attributable Profit in Fiscal H1

By

-- Fraser and Neave's (SGX:F99) attributable profit dropped to SG$81.6 million in the fiscal first half ended March 31, from SG$84.1 million a year earlier, according to a Wednesday filing with the Singapore Exchange.

Basic earnings per share stood at SG$0.056 compared with SG$0.058 in the year-ago period.

Revenue declined to SG$1.14 billion from SG$1.21 billion a year ago.

The food and beverage company declared an interim dividend of SG$0.015 per share, unchanged from a year earlier. The dividend will be paid on June 5.

Related Articles

Asia

CuFe Completes Expanded Scoping Study at Northern Territory Project; Shares Jump 10%

CuFe (ASX:CUF) said an expanded scoping study on its 55%-owned Orlando project in the Northern Territory shows a net present value of around AU$705 million on a 100%-ownership basis, internal rate of return of 111%, and payback period of 10 months, according to a Wednesday Australian bourse filing.This improves to a net present value of around AU$908 million on a 100% ownership basis if spot prices as of April 8 are used, the company said.The Orlando project is part of the wider Orlando/Gecko project in which CuFe Tennant Creek holds a 55% stake and Gecko Mining, a subsidiary of Gold Valley Group, holds a 45% stake.The expanded study is based on a standalone development of the Orlando deposit, including the construction of a new processing plant, with plant purchase and installation costs of AU$86 million comprising the majority of the estimated AU$141 million total pre-production capital expenditure.The company is considering a cutback to the existing Orlando open pit, re-establishing underground operations and the installation of the plant capable of producing copper, gold, bismuth, and silver, per the filing.CuFe's shares rose past 10% in recent trading on Wednesday.

$ASX:CUF
Asia

SSY Group Receives China Approval for Three Drugs

Pharmaceutical firm SSY Group (HKG:2005) said it received drug production and registration approvals for three of its products in China, according to a Hong Kong bourse filing Wednesday.The approval from China's National Medical Products Administration covers a fat-soluble vitamin injection, metformin hydrochloride tablets for type 2 diabetes, and doxazosin mesylate extended release tablets for benign prostatic hyperplasia and hypertension.

$HKG:2005
Asia

Andon Health Plans to Sell Repurchased Shares

Andon Health (SHE:002432) plans to sell 9,295,000 repurchased shares through centralized bidding, according to a Wednesday disclosure on the Shenzhen bourse filing.The shares represent not more than 2% of the Chinese medical devices company's total share capital.The repurchased shares will be sold within six months.Proceeds from the sale will be used to fund business operations, including product research and development and technological investments.The company's shares fell 2% during recent trade.

$SHE:002432